Skip Navigation

AIDSInfo logo

 
Home > Drugs > AMD070

AMD070
Drug Class: Entry and Fusion Inhibitors
AMD070, also known as AMD11070, is a type of medicine called a CXCR4 inhibitor. This type of medicine works by blocking the entry of HIV into cells.

HIV/AIDS-Related Uses
AMD070 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It is being studied for the treatment of HIV infection. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

Dosage Form/Administration
AMD070 comes in capsule form and is being studied to determine whether it should be taken with or without food. A solution form has been studied in animals in preclinical trials.

Contraindications
Individuals should tell a doctor about any medical problems before taking this medicine.

Possible Side Effects
Along with its desired effects, AMD070 can cause some unwanted effects. Because this drug has not been studied extensively in people, these effects are not yet known. In animal studies, the most common side effects are vomiting and diarrhea, which usually occur within 1 to 2 hours of taking the drug. Other side effects include changes in the bone marrow and thymus, elevated heart rate, and changes in blood pressure. The most common side effects occurring in studies with HIV infected patients are mild stomach upset and headache.

Drug and Food Interactions
A doctor should be notified of any other medications being taken, including prescription, nonprescription (over-the-counter), or herbal medications.

Clinical Trials
Click here to search ClinicalTrials.gov for trials that use AMD070.

Manufacturer Information
AMD070
  Genzyme Corporation
  500 Kendall Street
  Cambridge,  MA  02142
  (617) 252-7500
    
Updated December 2, 2008